atezolizumab + ipatasertib

The combination of atezolizumab and ipatasertib represents a therapeutic approach that combines immune checkpoint blockade with AKT pathway inhibition for cancer treatment, particularly in triple-negative breast cancer (TNBC). This combination has been studied in several clinical trials, often with the addition of a taxane (paclitaxel or nab-paclitaxel) as a triplet therapy. ## Mechanism of Action Atezolizumab is a PD-L1 inhibitor that works by blocking the PD-L1 pathway, potentially enhancing the immune system's ability to identify and attack tumor cells. It affects the immune system by preventing the PD-L1 pathway from controlling the body's natural immune response, which can be particularly important in certain cancers where the immune system is prevented from attacking tumors[4][5]. Ipatasertib is an oral, selective AKT inhibitor that competitively binds and inactivates the phosphorylated AKT complex, disrupting the mTOR pathway[6]. It targets the PI3K/AKT/mTOR pathway, which is frequently dysregulated in various cancers, including triple-negative breast cancer. By inhibiting AKT signaling, ipatasertib can decrease cancer cell proliferation and tumor growth[6]. ## Clinical Development The combination has been evaluated in several clinical trials: 1. CO40151 (NCT03800836) - A Phase Ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic TNBC[3][7]. 2. IPATunity130 (NCT03337724) - Included a single-arm signal-seeking cohort evaluating the triplet regimen of ipatasertib, atezolizumab, and paclitaxel as first-line therapy for locally advanced/metastatic TNBC[1][7]. 3. IPATunity170 (NCT04177108) - A Phase III, double-blind, placebo-controlled, randomized study of ipatasertib in combination with atezolizumab and paclitaxel for patients with locally advanced unresectable or metastatic TNBC[2][7]. 4. A study in glioblastoma patients combining ipatasertib and atezolizumab, showing preliminary evidence of antitumor activity, particularly in patients with PTEN loss[8]. ## Efficacy and Safety In the triplet combination studies for TNBC, efficacy outcomes varied across trials: - Median progression-free survival: 5.4 to 7.4 months - Objective response rate: 44% to 63% - Median duration of response: 5.6 to 11.1 months - Median overall survival: 15.7 to 28.3 months[7] The safety profile was consistent with the known toxicities of each agent, with Grade ≥3 adverse events being more frequent with the triplet than with doublets or single-agent paclitaxel[7]. Molecular characteristics may help identify patients who would benefit most from this combination therapy. Patients with PFS >10 months were characterized by NF1, CCND3, and PIK3CA alterations and increased immune pathway activity, while PFS <5 months was associated with CDKN2A/CDKN2B/MTAP alterations and lower predicted phosphorylated AKT-S473 levels[7]. This combination represents a rational therapeutic strategy aimed at improving efficacy through targeting multiple pathways simultaneously in cancer treatment.